$CATALYST\ PHARMACEUTICAL\ PARTNERS,\ INC.$

Form 8-K September 15, 2011

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

September 14, 2011

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED)

Commission File No. 001-33057

CATALYST PHARMACEUTICAL PARTNERS, INC.

 $(Exact\ Name\ Of\ Registrant\ As\ Specified\ In\ Its\ Charter)$

Edgar Filing: CATALYST PHARMACEUTICAL PARTNERS, INC. - Form 8-K

Delaware 76-0837053
(State Or Other Jurisdiction Of (IRS Employer

Incorporation Or Organization)

Identification No.)

355 Alhambra Circle, Suite 1370

Coral Gables, Florida 33134

(Address Of Principal Executive Offices)

(305) 529-2522

(Registrant s Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- " Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: CATALYST PHARMACEUTICAL PARTNERS, INC. - Form 8-K

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 14, 2011, Catalyst Pharmaceutical Partners, Inc. (Company) and its Chairman, President and Chief Executive Officer, Patrick J. McEnany, entered into an amendment to Mr. McEnany s employment agreement with the Company extending the term of such agreement for an additional two year period. Mr. McEnany s employment agreement with the Company now expires on November 8, 2013. All of the other terms of Mr. McEnany s employment agreement with the Company remain the same.

A copy of Amendment No. 3 to Mr. McEnany s employment agreement with the Company is attached hereto as Exhibit 10.1 and is incorporated herein by reference. The description of Amendment No. 3 that is set forth above is qualified in its entirety by reference to such amendment.

Item 9.01 Financial Statements and Exhibits

- (d) Exhibits
- 10.1 Amendment No. 3 to Employment Agreement between the Company and Patrick J. McEnany, dated September 14, 2011.

Edgar Filing: CATALYST PHARMACEUTICAL PARTNERS, INC. - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Catalyst Pharmaceutical Partners, Inc.

By: /s/ Jack Weinstein Jack Weinstein Vice President, Treasurer, and CFO

Dated: September 15, 2011